Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Looking Into Exagen’s Return On Capital Employed
Exagen (NASDAQ:XGN) brought in sales totaling $12.77 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 3.14%, resulting in a loss of $5.74 million.
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Exagen Stock Gains As Q2 Financials Surpass Street Expectations
Exagen Inc (NASDAQ:XGN) shares are moving after the Company’s Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased…
54 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Exagen: Q2 Earnings Insights
Shares of Exagen (NASDAQ:XGN) fell after the company reported Q2 results.
Quarterly Results
Earnings per share were down 40.74% over the past year to ($0.38), which beat the estimate of ($0.44).
Exagen Q2 EPS $(0.38) Beats $(0.44) Estimate, Sales $12.80M Beat $11.48M Estimate
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 40.74 percent decrease over losses of $(0.27) per share from the same
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.